Article
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Molecular cancer therapeutics - 1 Aug 2016
Black Jonathan, Menderes Gulden, Bellone Stefania, Schwab Carlton L, Bonazzoli Elena, Ferrari Francesca, Predolini Federica, De Haydu Christopher, Cocco Emiliano, Buza Natalia, Hui Pei, Wong Serena, Lopez Salvatore, Ratner Elena, Silasi Dan-Arin, Azodi Masoud, Litkouhi Babak, Schwartz Peter E, Goedings Peter, Beusker Patrick H, van der Lee Miranda M C, Timmers C Marco, Dokter Wim H A, Santin Alessandro D
Abstract excerpt
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu oncogene at strong (i.e., 3+) levels by IHC while an additional 40% to 50% express HER2/neu at moderate (2+) or low (1+) levels. We investigated the efficacy of SYD985, (Synthon Biopharmaceuticals), a novel HER2-targeting antibody-drug conjugate (ADC) composed of the mAb trastuzumab linked to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.